377 related articles for article (PubMed ID: 29335623)
21. Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program.
Kernan NA; Richardson PG; Smith AR; Triplett BM; Antin JH; Lehmann L; Messinger Y; Liang W; Hume R; Tappe W; Soiffer RJ; Grupp SA
Pediatr Blood Cancer; 2018 Oct; 65(10):e27269. PubMed ID: 29873895
[TBL] [Abstract][Full Text] [Related]
22. [Diagnosis and treatment of sinusoidal obstruction syndrome (veno-occlusive disease)].
Kikuta A
Rinsho Ketsueki; 2021; 62(8):1256-1264. PubMed ID: 34497214
[TBL] [Abstract][Full Text] [Related]
23. Incidence of Anicteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients.
Corbacioglu S; Kernan NA; Pagliuca A; Ryan RJ; Tappe W; Richardson PG
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1342-1349. PubMed ID: 32200121
[TBL] [Abstract][Full Text] [Related]
24. Veno-occlusive disease after high-dose busulfan-melphalan in neuroblastoma.
Schechter T; Perez-Albuerne E; Lin TF; Irwin MS; Essa M; Desai AV; Frangoul H; Yanik G; Dupuis LL; Jacobsohn D; Kletzel M; Ranalli M; Soni S; Seif AE; Grupp S; Dvorak CC
Bone Marrow Transplant; 2020 Mar; 55(3):531-537. PubMed ID: 30181580
[TBL] [Abstract][Full Text] [Related]
25. Cost-Effectiveness of Defibrotide in the Prophylaxis of Veno-Occlusive Disease after Pediatric Allogeneic Stem Cell Transplantation.
Pichler H; Horner K; Engstler G; Poetschger U; Glogova E; Karlhuber S; Martin M; Eibler W; Witt V; Holter W; Matthes-Martin S
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1128-1133. PubMed ID: 28359910
[TBL] [Abstract][Full Text] [Related]
26. Absence of veno-occlussive disease in a cohort of multiple myeloma patients undergoing autologous stem cell transplantation with targeted busulfan dosage.
Clopés A; Sureda A; Sierra J; Queraltó JM; Broto A; Farré R; Moreno E; Brunet S; Martino R; Mangues MA
Eur J Haematol; 2006 Jul; 77(1):1-6. PubMed ID: 16573745
[TBL] [Abstract][Full Text] [Related]
27. A Systematic Review and Meta-Analysis of Studies of Defibrotide Prophylaxis for Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.
Corbacioglu S; Topaloglu O; Aggarwal S
Clin Drug Investig; 2022 Jun; 42(6):465-476. PubMed ID: 35594010
[TBL] [Abstract][Full Text] [Related]
28. Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome.
Richardson PG; Triplett BM; Ho VT; Chao N; Dignan FL; Maglio M; Mohty M
Expert Rev Clin Pharmacol; 2018 Feb; 11(2):113-124. PubMed ID: 29301447
[TBL] [Abstract][Full Text] [Related]
29. Reduced Risk of Sinusoidal Obstruction Syndrome of the Liver after Busulfan-Cyclophosphamide Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation.
El-Serafi I; Remberger M; Ringdèn O; Törlén J; Sundin M; Björklund A; Winiarski J; Mattsson J
Clin Transl Sci; 2020 Mar; 13(2):293-300. PubMed ID: 31675173
[TBL] [Abstract][Full Text] [Related]
30. Validation of treatment outcomes according to revised severity criteria from European Society for Blood and Marrow Transplantation (EBMT) for sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD).
Yoon JH; Yoo KH; Sung KW; Jung CW; Kim JS; Hahn SM; Kang HJ; Lee JH; Im HJ; Ahn JS; Kook H; Cho B; Lee JW
Bone Marrow Transplant; 2019 Aug; 54(8):1361-1368. PubMed ID: 30809031
[TBL] [Abstract][Full Text] [Related]
31. Transjugular Intrahepatic Portosystemic Shunt for Very Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with Post-transplantation Cyclophosphamide.
Gómez-Centurión I; Bailén R; Oarbeascoa G; Muñoz C; Luque AÁ; Boyra ME; Calleja E; Rincón D; Dorado N; Barzallo P; Anguita J; Díez-Martín JL; Kwon M
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2089-2097. PubMed ID: 32791193
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant.
Pai RK; van Besien K; Hart J; Artz AS; O'Donnell PH
Leuk Lymphoma; 2012 Aug; 53(8):1552-7. PubMed ID: 22280517
[TBL] [Abstract][Full Text] [Related]
33. Incidence of Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease and Treatment with Defibrotide in Allogeneic Transplantation: A Multicenter Australasian Registry Study.
Coutsouvelis J; Kirkpatrick CM; Dooley M; Spencer A; Kennedy G; Chau M; Huang G; Doocey R; Copeland TS; Do L; Bardy P; Kerridge I; Cole T; Fraser C; Perera T; Larsen SR; Mason K; O'Brien TA; Shaw PJ; Teague L; Butler A; Watson AM; Ramachandran S; Marsh J; Khan Z; Hamad N
Transplant Cell Ther; 2023 Jun; 29(6):383.e1-383.e10. PubMed ID: 36934993
[TBL] [Abstract][Full Text] [Related]
34. Pooled analysis of Day 100 survival for defibrotide-treated patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation.
Richardson PG; Smith AR; Kernan NA; Lehmann L; Soiffer RJ; Ryan RJ; Tappe W; Grupp S
Br J Haematol; 2020 Aug; 190(4):583-587. PubMed ID: 32157682
[TBL] [Abstract][Full Text] [Related]
35. Hepatic sinusoidal obstruction syndrome/veno-occlusive disease after hematopoietic cell transplantation: historical and current considerations in Korea.
Yoon JH; Choi CW; Won JH
Korean J Intern Med; 2021 Nov; 36(6):1261-1280. PubMed ID: 34555279
[TBL] [Abstract][Full Text] [Related]
36. Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome.
Kernan NA; Grupp S; Smith AR; Arai S; Triplett B; Antin JH; Lehmann L; Shore T; Ho VT; Bunin N; Iacobelli M; Liang W; Hume R; Tappe W; Soiffer R; Richardson P
Br J Haematol; 2018 Jun; 181(6):816-827. PubMed ID: 29767845
[TBL] [Abstract][Full Text] [Related]
37. Targeted-dose of busulfan: Higher risk of sinusoidal obstructive syndrome observed with systemic exposure dose above 5000 µMol⸱min. A historically controlled clinical trial.
Esteves I; Santos FPS; Ribeiro AAF; Seber A; Sugawara EK; Sobrinho JJDN; Barros JC; Oliveira JSR; Fernandes JF; Hamerschlak N; Andersson BS; de Lima M; Kerbauy FR
Hematol Oncol; 2020 Dec; 38(5):773-781. PubMed ID: 32779746
[TBL] [Abstract][Full Text] [Related]
38. Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program.
Corbacioglu S; Carreras E; Mohty M; Pagliuca A; Boelens JJ; Damaj G; Iacobelli M; Niederwieser D; Olavarría E; Suarez F; Ruutu T; Verdonck L; Hume R; Nejadnik B; Lai C; Finetto G; Richardson P
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1874-1882. PubMed ID: 27397724
[TBL] [Abstract][Full Text] [Related]
39. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy.
Haussmann U; Fischer J; Eber S; Scherer F; Seger R; Gungor T
Haematologica; 2006 Jun; 91(6):795-800. PubMed ID: 16769582
[TBL] [Abstract][Full Text] [Related]
40. Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous Busulphan.
Cappelli B; Chiesa R; Evangelio C; Biffi A; Roccia T; Frugnoli I; Biral E; Noè A; Fossati M; Finizio V; Miniero R; Napolitano S; Ferrua F; Soliman C; Ciceri F; Roncarolo MG; Marktel S
Br J Haematol; 2009 Nov; 147(4):554-60. PubMed ID: 19747363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
